₹679.4 -4.0 -0.6%
Last Trade - 11:28am
| Market Cap | £16.01bn |
| Enterprise Value | £16.14bn |
| Revenue | £3.24bn |
| Position in Universe | 24th / 3105 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 273,920 | 284,870 | 315,784 | 264,895 | 290,659 | 328,375 | 337,874 | 375,192 | +3.7% | ||
| -20.6 | +5.9 | +35.5 | -55.8 | +21.6 | +6.5 | +50.4 | +2.27 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 1, 1993 |
| Public Since | January 1, 1994 |
| No. of Shareholders: | 654,242 |
| No. of Employees: | 36,000 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | S&P BSE 100 , S&P BSE Sensex , Nifty 50 , |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 2,399,334,970 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Acme Plaza,Andheri Kurla Road Andheri East, MUMBAI, 400063, India |
| Web | http://www.sunpharma.com/ |
| Phone | +91 22 43244324 |
| Contact | Nimish Desai (IR Officer) |
| Auditors | Deloitte Haskins & Sells LLP |
As of 11:28am, shares in Sun Pharmaceutical Industries are trading at ₹679.4, giving the company a market capitalisation of £16.01bn. This share price information is delayed by 15 minutes.
Shares in Sun Pharmaceutical Industries are currently trading at ₹679.4 and the price has moved by 49.77% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sun Pharmaceutical Industries price has moved by -5.28% over the past year.
Of the analysts with advisory recommendations for Sun Pharmaceutical Industries, there are there are currently 14 "buy" , 1 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Sun Pharmaceutical Industries is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sun Pharmaceutical Industries is scheduled to issue upcoming financial results on the following dates:
The Sun Pharmaceutical Industries dividend yield is 0.95% based on the trailing twelve month period.
Last year, Sun Pharmaceutical Industries paid a total dividend of 6.5, and it currently has a trailing dividend yield of 0.95%. Looking ahead, Sun Pharmaceutical Industries has not announced an ex-dividend date yet.
Sun Pharmaceutical Industries has yet to annouce their ex-dividend date. The historic dividend yield on Sun Pharmaceutical Industries shares is currently 0.95%.
To buy shares in Sun Pharmaceutical Industries you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Sun Pharmaceutical Industries are currently trading at ₹679.4, giving the company a market capitalisation of £16.01bn.
Here are the trading details for Sun Pharmaceutical Industries:
Based on an overall assessment of its quality, value and momentum, Sun Pharmaceutical Industries is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Sun Pharmaceutical Industries are currently priced at ₹679.4. At that level they are trading at 1.84% premium to the analyst consensus target price of 0.00.
Analysts covering Sun Pharmaceutical Industries currently have a consensus Earnings Per Share (EPS) forecast of 25.001 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sun Pharmaceutical Industries. Over the past six months, the relative strength of its shares against the market has been 12.42%. At the current price of ₹679.4, shares in Sun Pharmaceutical Industries are trading at 22.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sun Pharmaceutical Industries PE ratio based on its reported earnings over the past 12 months is 31.04. The shares are currently trading at ₹679.4.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sun Pharmaceutical Industries's management team is headed by:
Here are the top five shareholders of Sun Pharmaceutical Industries based on the size of their shareholding:
